SCHEMBL873738

SCHEMBL873738

C[C@]1(O)C(n2cnc3c(N)nc(N)nc32)O[C@H](CO)[C@H]1O

nearest known ligand 0.80

Predicted protein targets (top 8)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 7/20 0.80
ADA P00813 1/20 0.69
ADORA3 P0DMS8 8/20 0.56
ADORA1 P30542 6/20 0.56
ADORA2B P29275 4/20 0.56
ALOX15 P16050 1/20 0.56
AHCY P23526 1/20 0.50
CYP2C19 P33261 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14589609 1.00 ADORA2A (0.80) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL15908433 1.00 ADORA2A (0.80) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL10169502 1.00 ADORA2A (0.80) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL474849 1.00 ADORA2A (0.80) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL10137892 1.00 ADORA2A (0.80) ADORA2AADAADORA3ADORA1ADORA2B
2'-B-Methyl-Guanosine SCHEMBL11888942 0.90 ADORA2A (0.69) ADORA2AADAADORA3ADORA1ADORA2B
2'-B-Methyl-Guanosine SCHEMBL939849 0.90 ADORA2A (0.69) ADORA2AADAADORA3ADORA1ADORA2B
2'-B-Methyl-Guanosine SCHEMBL10316549 0.90 ADORA2A (0.69) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL29848577 0.90 ADORA2A (0.78) ADORA2AADAADORA3ADORA1ADORA2B
SCHEMBL28952403 0.90 ADORA2A (0.78) ADORA2AADAADORA3ADORA1ADORA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2953462-A2 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C Merck Sharp & Dohme Corp. (US) 2015-12-16 EP disclosed
EP-2953456-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C Merck Sharp & Dohme Corp. (US) 2015-12-16 EP disclosed
EP-2953461-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C Merck Sharp & Dohme Corp. (US) 2015-12-16 EP disclosed
WO-2014123793-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2014-08-14 WO disclosed
WO-2014123794-A1 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2014-08-14 WO disclosed
WO-2014123795-A2 TETRACYCLIC HETEROCYCLE COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF HEPATITIS C MERCK SHARP & DOHME CORP. (US) 2014-08-14 WO disclosed
EP-2618665-A1 HCV NS3 PROTEASE INHIBITORS Merck Sharp & Dohme Corp. (US) 2013-07-31 EP disclosed
EP-2542545-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE Merck Sharp & Dohme Corp. (US) 2013-01-09 EP disclosed
WO-2012040040-A1 HCV NS3 PROTEASE INHIBITORS MERCK SHARP & DOHME CORP. (US) 2012-03-29 WO disclosed
WO-2011106992-A1 INHIBITORS OF HEPATITIS C VIRUS NS5B POLYMERASE MERCK SHARP & DOHME CORP. (US) 2011-09-09 WO disclosed